Acute Effects of Coffee on Appetite and Inflammation Markers, Glucose Metabolism and Energy Intake

• Register: ClinicalTrials.gov
• Last refreshed on: 19 October 2017
• Main ID: NCT01174576
• Date of registration: 26/07/2010
• Prospective Registration: No
• Primary sponsor: Harokopio University
• Public title: Acute Effects of Coffee on Appetite and Inflammation Markers, Glucose Metabolism and Energy Intake
• Scientific title: Acute Effects of Caffeinated and Decaffeinated Coffee Consumption on Energy Intake, Appetite, Inflammation and Glucose Metabolism
• Date of first enrolment: February 2009
• Target sample size: 16
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT01174576
• Study type: Interventional
• Phase: N/A

Countries of recruitment

Greece

Contacts

• Name: Mary Yannakoulia, PhD
• Affiliation: Harokopio University

Key inclusion & exclusion criteria

Inclusion Criteria:

- healthy

- non-obese

Exclusion Criteria:

- smokers

- restrained eaters (as this was evaluated using the Dutch Eating Behaviour
Questionnaire and a total score > 2.5)

- those who reported slimming or any other dietary regime

- abstainers from caffeine sources

- athletes during competition period

- participants with a known diagnosis of either hypertension, diabetes, impaired glucose
tolerance or a fasting blood glucose concentration above 125 mg/dl

- subjects on medication for hypertension or on medication known to alter glucose
metabolism

- subjects who were on medication that may have an impact on appetite and sensory
functioning or who reported a metabolic or endocrine disease, gastrointestinal
disorders, or a history of medical or surgical events that may have affected the study
outcomes



Age minimum: 18 Years
Age maximum: 40 Years
Gender: Male

Health Condition(s) or Problem(s) studied

Health

Intervention(s)

Other: caffeinated and decaffeinated coffee

Primary Outcome(s)

Cortisol Total Area Under the Curve [Time Frame: 15 min before ingestion to 3 hr post ingestion]

Peptide Tyrosine Tyrosine (PYY) Total Area Under the Curve [Time Frame: 15 min before ingestion to 3 hr post ingestion]

Interleukin-18 Total Area Under the Curve [Time Frame: 15 min before ingestion to 3 hr post ingestion]

Glucagon-like Peptide-1 (GLP-1) Total Area Under the Curve [Time Frame: 15 min before ingestion to 3 hr post ingestion]

Adiponectin Total Area Under the Curve [Time Frame: 15 min before ingestion to 3 h post ingestion]

Energy ad Libitum Meal [Time Frame: 3 hr post ingestion]

Glucose Total Area Under the Curve [Time Frame: 15 min before ingestion to 3 hr post ingestion]

Insulin Total Area Under the Curve [Time Frame: 15 min before ingestion to 3 hr post ingestion]

Ghrelin Total Area Under the Curve [Time Frame: 15 min before ingestion to 3 hr post ingestion]

Inteleukin-6 Total Area Under the Curve [Time Frame: 15 min before ingestion to 3 hr post ingestion]

Total Energy Intake [Time Frame: 1 d]

Secondary Outcome(s)

Serum Antioxidant Capacity Total Area Under the Curve [Time Frame: 15 min before ingestion to 21/2 hr post ingestion]

Secondary ID(s)

CofSt

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Beth Israel Deaconess Medical Center

Results

• Results available: Yes
• Date Posted: 30/09/2013
• URL: https://clinicaltrials.gov/ct2/show/results/NCT01174576